- FSD Pharma (HUGE) is sharing pre-clinical data demonstrating the potentially disease-modifying effects of its lead drug candidate Lucid-MS in mice
- The company has released a video explaining its pre-clinical results, including visual evidence of functional recovery on pre-clinical subjects
- Anthony Durkacz, interim CEO at FSD Pharma sat down with Caroline Egan to discuss the drug candidate and the exciting results demonstrated in the video
- FSD Pharma is a biotechnology company with three drug candidates in different stages of development
- FSD Pharma Inc. (HUGE) opened trading at C$1.45 per share
FSD Pharma (HUGE) is sharing pre-clinical data demonstrating the potentially disease-modifying effects of its lead drug candidate Lucid-MS.
Lucid-MS is the company’s lead drug candidate for the potential treatment of multiple sclerosis (MS).
Anthony Durkacz, interim CEO at FSD Pharma sat down with Caroline Egan to discuss Lucid-MS and the exciting visual evidence shown in this video.
FSD Pharma is also advancing the development of its other drug candidates, including Lucid-PSYCH, a psychoactive molecule targeted to treat Major Depressive Disorder, and FSD-PEA, an anti-inflammatory compound.
FSD Pharma is a biotechnology company with three drug candidates in different stages of development. Through the company’s wholly-owned subsidiary, Lucid, FSD Pharma is also focused on the research and development of its lead compounds, Lucid-PSYCH (formerly Lucid-201) and Lucid-MS (formerly Lucid-21-302). Lucid PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders.
FSD Pharma Inc. (HUGE) opened trading at C$1.45 per share.
